Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI-0001 in CD19+ Leukemia or Lymphoma
NCT03144583Phase 1Completed
- Start
- Jun 2017
- Primary completion
- Sep 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ARI-0001 in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and 2 more. Primary endpoints: Procedure-related mortality at 3 years and Assessment of toxicity at 1 year. Started Jun 2017; status: completed.
02
Drugs
ARI-0001
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)follicular lymphoma (FL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03144583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144583.